节点文献

首发精神分裂症患者利培酮疗效与COMT基因多态性关联研究

Association studies of COMT gene polymorphisms with risperidone treatment in first-episode schizophrenia

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 李波黎雪松龚道元谢国军陈家强彭艳王晓娟

【Author】 LI Bo*, LI Xue-song,GONG Dao-yuan,XIE Guo-jun,CHEN Jia-qiang,PENG Yan,WANG Xiao-juan. *Faculty of laboratory medicine and pharmacy, Medical College, FoShan University of Science and Technology, Foshan, Guangdong 528000, China

【机构】 佛山科学技术学院医学院检验与药学系广东省佛山市第三人民医院

【摘要】 目的:探讨首发精神分裂症患者COMT基因多态性与利培酮疗效的关系。方法:100例首发精神分裂症患者使用利培酮治疗8周,以PANSS量表评定疗效;SNaPshot SNP检测COMT基因rs4680和rs4818多态性。结果:利培酮有效组与无效组相比,精神分裂症患者rs4680基因型G/G与A/G、A/A的分布差异具有显著性(χ2=5.334,P<0.05),rs4680G/G基因型与利培酮疗效之间存在明显关联(OR=1.78,P<0.05)。结论:rs4680多态性与利培酮治疗首发精神分裂症的临床疗效相关。

【Abstract】 Objective To investigate the association of catechol-O-methyltransferase (COMT) gene polymorphisms with response of risperidone treatment in first-episode schizophrenia. Methods One hundred cases of schizophrenic patients were chosen to treat with risperidone for 8 weeks. The efficacy of antipsychotic medication was evaluated by PANSS scale. Allelic typing of COMT was detected by SNaPshot SNP technique. Results The distribution of rs4680 genotype G/G, A/G and A/A had significant difference between risperidone responder group and nonresponder group(χ2 = 5.334,P < 0.05) and rs4680 G/G genotype was correlated with the efficacy of risperidone (OR = 1.78,P < 0.05). Conclusion The polymorphisms of rs4680 related with effects of risperidone on first-episode schizophrenia.

【基金】 广东省科技计划项目(编号:2009B030801372)
  • 【文献出处】 实用医学杂志 ,The Journal of Practical Medicine , 编辑部邮箱 ,2013年04期
  • 【分类号】R749.3
  • 【被引频次】10
  • 【下载频次】103
节点文献中: 

本文链接的文献网络图示:

本文的引文网络